1.92
-0.52%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Solana
From its filings with the US Securities and Exchange Commission
Solana is based in Philadelphia, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker HSDT. The SEC classifies its business as finance services. In the fiscal year to 31 December 2025, it reported revenue of $6.0m and a net loss of $40.9m. At that date it held total assets of $303.9m and shareholders' equity of $300.9m.
We are a listed digital asset treasury (“DAT”) dedicated to acquiring and holding Solana tokens (“SOL”). Solana Company’s DAT objective is to maximize SOL per share through strategic use of capital markets and onchain opportunities, offering public market investors direct exposure to Solana.
Strategic digital asset reserves like SOL lay the groundwork for a future where global payments, credentialing, and personalized learning can be powered by decentralized infrastructure, enhancing how we grow our company. We believe that Solana represents a uniquely scalable, high-performance blockchain platform that aligns with our long-term vision of integrating innovative technologies into our services. By investing in and participating in the Solana ecosystem, we aim to both enhance our digital asset treasury strategy and create strategic optionality for product innovation in our core business.
We are, to a lesser extent, also a neurotechnology company focused on neurological wellness.
In September 2025, we adopted a digital asset treasury strategy centered on acquiring SOL and began repositioning a substantial portion of our balance sheet around that strategy. We expect the digital asset treasury strategy to be our principal strategic focus. Our assets are expected to remain concentrated primarily in SOL.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 27 Jun 2014
- Employees
- 21
- Website
- heliusmedical.com ↗
- Head office
- 1650 MARKET STREET, PHILADELPHIA, PA, 19103
- Incorporated in
- DE
- Classification
- Finance Services
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Joseph CheeExecutive Chairman of the Board, since 2025
- Mr. Dane AndreeffPresident, Chief Executive Officer, Director, since 2017$1.3m
- Mr. Jeffrey MathiesenChief Financial Officer, Treasurer, Secretary, Director, since 2020$874,024
- Dr. Antonella Favit-Van PeltChief Medical Officer$755,451
- Mr. Paul BuckmanIndependent Director$93,146
- Ms. Sherrie PerkinsIndependent Director$79,646
- Vice Adm. (Retd.) Edward StrawIndependent Director$90,146
- Mr. Blane WalterIndependent Director$108,146
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 15
- Environment
- 17
- Social
- 16
- Governance
- 13
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Solana Co develops the PoNS device for neurological wellness in the Health Care sector.
- The company's PoNS device is a class II medical device authorized in Canada for balance deficit treatment.
- Solana Co focuses on non-invasive platform technologies that amplify the brain's healing ability.
Weaknesses
- Solana Co has only 21 employees, which may limit operational capacity.
- The company's IPO was in 2014, indicating limited recent market presence.
- Solana Co's business is confined to the Health Care sector with no diversification.
Opportunities
- The PoNS device has potential for expansion in the Canadian market for mmTBI treatment.
- Solana Co could explore new applications for its non-invasive neurostimulation technology.
- The growing focus on neurological wellness presents opportunities for Solana Co in Health Care.
Threats
- The PoNS device is limited to a 14-week treatment period, restricting long-term use.
- Regulatory changes in Canada could affect the authorization of the PoNS device.
- Solana Co faces competition from other neurotech companies in the Health Care industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.